Physician profile
Daniel Krug
NPI 1407595184
$6,326.12
in general payments reported to CMS, 2019-2025
13 companies · $1,964 in 2025
The $1,964 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $105 · 2023: $2,462 · 2024: $1,796 · 2025: $1,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,237 · Travel and Lodging: $1,966 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,237.03 |
| Travel and Lodging | $1,966.47 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,437.83 | 2022-2025 | Air Optix, Dailies Aqua Comfort Plus, Dailies Total1 Multifocal |
| Bausch & Lomb Americas INC. | $1,001.74 | 2023-2025 | Infuse, Miebo, Xiidra |
| Abbvie INC. | $362.23 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $357.99 | 2023-2024 | Cequa |
| Tarsus Pharmaceuticals, INC. | $248.85 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $240.02 | 2024 | Tecnis Iol |
| Ocular Therapeutix, INC. | $125.98 | 2024 | Dextenza |
| Oyster Point Pharma, INC. | $125.00 | 2024 | Tyrvaya |
| Harrow Eye, LLC | $125.00 | 2025 | Vevye |
| Amgen INC. | $121.85 | 2024 | |
| Horizon Therapeutics Plc | $66.12 | 2023 | Tepezza |
| Carl Zeiss Meditec, INC. | $66.00 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $47.51 | 2022-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Krug listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.